Clinical Trial Detail

NCT ID NCT03087448
Title Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors University of California, San Francisco
Indications

non-small cell lung carcinoma

Therapies

Ceritinib + Trametinib

Age Groups: adult senior

Additional content available in CKB BOOST